Impact of Statin Pretreatment on the Complications of Carotid Stenting in Asymptomatic Patients: Observational Study

Seong Hwa Jang
Keimyung University Dongsan Medical Center

Doo Hyuk Kwon
Keimyung University Dongsan Medical Center

Moon-Ku Han
Seoul National University Bundang Hospital

Hyungjong Park
Keimyung University Dongsan Medical Center

Sung-II Sohn
Keimyung University Dongsan Medical Center

Huimahn Choi
The University of Texas Health Science Center at Houston

Jeong-Ho Hong (✉ neurohong79@gmail.com)
Keimyung University Dongsan Medical Center

Research Article

Keywords: carotid stenosis, stents, complications, statin

DOI: https://doi.org/10.21203/rs.3.rs-117587/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Carotid stenosis is a known risk factor for ischemic stroke, and carotid artery stenting is an effective preventive procedure. However, the stroke risk reduction for asymptomatic patients is small. Therefore, it is important to reduce the risk of complications, particularly in asymptomatic carotid stenosis. Statins are known to reduce the overall risk of periprocedural complications, although there is a lack of data focusing on asymptomatic patients. We aimed to investigate whether different doses of statin pretreatment can reduce periprocedural complications of carotid artery stenting in patients with asymptomatic carotid artery stenosis.

**Methods:** Between July 2003 and June 2013, 276 consecutive patients received carotid artery stenting (CAS) for asymptomatic carotid stenosis. Periprocedural complications included the outcome of stroke, myocardial infarction, or death within 30 days of CAS. Statin pretreatment was categorized as no-statin (n=87, 31.5%), standard-dose (<40 mg, n=139, 50.4%), and high-dose statin (≥40 mg, n=50, 18.1%) according to the atorvastatin equivalent dose. Cochran-Armitage (CA) trend test was performed for periprocedural complications to investigate the association with statin dose.

**Results:** The overall periprocedural complication rate was 3.3%. There was no significant difference in the risk of periprocedural complications between the three groups (no statin: n=3 [3.4%]; standard-dose: n=4 [2.9%]; high-dose n=2 [4.0%] \( p = 0.923 \)). CA trend test did not demonstrate a trend in the proportion of periprocedural complications across increasing statin equivalent dose (\( p = 0.919 \)).

**Conclusions:** Statin pretreatment before CAS showed neither absolute nor dose-dependent effects against periprocedural complications in asymptomatic patients with CAS.

Introduction

Carotid artery atheromatous disease accounts for approximately 10–20% of ischemic strokes.(1, 2) Carotid artery stenting (CAS) has grown substantially in use as an alternative definitive revascularization procedure to carotid endarterectomy (CEA) for carotid occlusive disease. In a cross-sectional analysis of US Medicare beneficiaries, the percentage of asymptomatic carotid artery stenosis among patients who underwent CAS between 1999 and 2014 was 83.1%.(3) However, the absolute risk reduction associated with CAS in patients with asymptomatic carotid artery stenosis is small.(4) Therefore, it is important to reduce periprocedural complications in asymptomatic patients with CAS.

Various treatments are available to reduce periprocedural complications.(5–7) In particular, statin therapy prior to CAS was associated with significant reductions in periprocedural risk.(6–8) In CEA, pre-statin therapy was shown to have a protective effect only in symptomatic patients, while it was not significant in asymptomatic patients.(9) Our previous study showed that statin pretreatment reduced the incidence of periprocedural complications dose-dependently in patients who underwent CAS for symptomatic carotid artery stenosis.(10) However, this dose-effectiveness has not yet been proven in patients with asymptomatic carotid artery stenosis.
We aimed to investigate whether statin pretreatment, according to statin dose, is associated with a reduction of periprocedural complications in patients with asymptomatic carotid stenosis who underwent CAS.

Methods

Study subjects and data collection

This study used retrospective CAS registry data from two tertiary university hospitals between July 2003 and June 2013. We included patients with asymptomatic carotid stenosis, defined as ≥ 60% stenosis of the carotid artery (according to North American Symptomatic Carotid Endarterectomy Trial criteria(11)) by digital subtraction angiography (DSA), in the absence of retinal or cerebral ischemia in the preceding six months. These criteria were benchmarked in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).(12)

We obtained clinical characteristics and procedure-related factors from our CAS registry database. All patients underwent clinical assessment at baseline, 24 hours after the procedure, and subsequently daily until discharge from the hospital. The statin name and dose were obtained from hospital data. According to the lipid reduction fraction, high-dose statin was defined as atorvastatin ≥ 40 mg/day, and standard-dose as atorvastatin < 40 mg based on the atorvastatin-equivalent dose.(13, 14) This study was approved by the Institutional Review Board of Keimyung University Dongsan Hospital. The requirement for informed consent was waived because of the retrospective nature of this study (IRB of Keimyung University Dongsan Hospital, IRB number 2017-05-042).

Stenting Procedure

All patients requiring CAS were treated following the current guidelines.(15) Stents and cerebral protection devices were chosen at the discretion of the neuro-interventionist. All patients received optimal medical treatment and control of vascular risk factors. Dual antiplatelet (aspirin + clopidogrel) was given routinely for at least seven days prior to the procedure. The use of intraprocedural heparin was mandatory, with a dose of 3000 U. Dilatation after stenting was discretionary. The degree of residual stenosis at the end of the procedure was determined based on DSA.

Outcomes and Definitions

Complications after CAS, such as the rates of transient ischemic attack (TIA), stroke, myocardial infarction or death, were analyzed according to pretreatment statin dose. Periprocedural complications were considered the combined outcome of any incidents of stroke, myocardial infarction, or death within 30 days of CAS. Definitions of each periprocedural complications are derived from previous study.(10)

Statistical analysis

Statistical variables are presented as medians (interquartile range, IQR) or frequencies (percentages). Comparative analyses between the no-statin, standard-dose, and high-dose statin groups were performed
for vascular risk factors, imaging findings, and periprocedural complications. Groups were compared using chi-square tests for categorical variables, ANOVA for parametric interval variables, or Kruskal-Wallis test for non-parametric interval variables. We assigned the sample median for missing values of the lipid profile because we assumed that missing data were occurring randomly. Multivariable logistic regression model was created to assess the impact of variables contributing to periprocedural complications. Variables from bivariate analysis at p < 0.15 were selected. In addition, Cochran-Armitage (CA) trend test was performed for periprocedural complications to investigate the possible association with the statin dose. Statistical analyses were calculated using R statistical software (R, version 3.6.2; R project).

**Results**

In our study, 276 patients were enrolled. The majority were male (83.7%), and the median age was 70.0 years (IQR, 64.0–74.0). Most patients had > 70% stenosis (95.6%). The most common vascular risk factor was hypertension (66.7%), followed by diabetes mellitus (42.4%), smoking (42.4%), and hyperlipidemia (33.7%). Prior to CAS, all patients were on antiplatelet treatment. The patients were allocated into three groups according to the atorvastatin equivalent dose: no-statin (n = 87, 31.5%), standard-dose (n = 139, 50.4%), and high-dose statin (n = 50, 18.1%). Overall baseline characteristics are presented in Table 1.

The groups according to statin dose did not differ significantly in age. In procedure-related characteristics, such as pre-stenting dilatation and post-stent dilatation, there was no difference between the three groups. Although the degree of stenosis was similar between the three groups (p = 0.207), residual stenosis was significantly higher in the high-dose statin group compared to other groups (p = 0.003). In terms of lipid profile, there were no significant differences between groups in high-density lipoproteins (HDL). However, the high-dose statin group had lower low-density lipoproteins (LDL) and total cholesterol (TC) than other groups. A summary of statin drugs and doses used is found in Supplementary Table I.
Table 1
Baseline characteristics of patients undergoing stenting for asymptomatic carotid artery stenosis

|                                | Total (N = 276) | No-statin (N = 87) | Standard-dose (N = 139) | High-dose (N = 50) | p-value |
|--------------------------------|----------------|--------------------|-------------------------|--------------------|---------|
| Age, years                     | 70.0 (64.0–74.0) | 70.0 (63.5–74.0)   | 70.0 (63.5–74.0)        | 69.0 (64.0–72.0)   | 0.417   |
| Sex, male                      | 231 (83.7%)     | 78 (89.7%)         | 114 (82.0%)             | 39 (78.0%)         | 0.154   |
| Vascular risk factors          |                |                    |                         |                    |         |
| Hypertension                   | 184 (66.7%)     | 52 (59.8%)         | 96 (69.1%)              | 36 (72.0%)         | 0.239   |
| Diabetes mellitus              | 117 (42.4%)     | 33 (37.9%)         | 62 (44.6%)              | 25 (50.0%)         | 0.363   |
| Hyperlipidemia                 | 93 (33.7%)      | 12 (13.8%)         | 63 (45.3%)              | 18 (36.0%)         | < 0.001 |
| Ischemic heart disease         | 51 (18.5%)      | 11 (12.6%)         | 28 (20.1%)              | 12 (24.0%)         | 0.198   |
| Atrial fibrillation            | 13 (4.7%)       | 3 (3.4%)           | 6 (4.3%)                | 4 (8.0%)           | 0.458   |
| Smoking                        | 117 (42.4%)     | 35 (40.2%)         | 63 (45.3%)              | 19 (38.0%)         | 0.591   |
| Total cholesterol              | 166.0 (140.0–194.0) | 181.0 (151.0–199.0) | 164.0 (135.5–192.0)   | 152.0 (135.0–178.0) | 0.008   |
| Triglyceride                   | 121.0 (88.0–165.5) | 120.5 (87.2–159.3) | 114.3 (83.9–155.5)     | 145.5 (113.5–177.5) | 0.048   |
| High-density lipoprotein       | 41.0 (35.0–49.0) | 42.0 (35.0–49.0)   | 41.0 (35.0–49.2)        | 40.0 (36.0–47.5)   | 0.954   |
| Low-density lipoprotein        | 91.0 (68.0–114.5) | 98.0 (81.0–118.9)  | 88.5 (66.0–113.0)       | 71.0 (57.5–113.2)  | 0.048   |
| Pre-stenting antiplatelet      | 276 (100%)      | 87 (100%)          | 139 (100%)              | 50 (100%)          | 1.000   |
| Degree of stenosis             |                |                    |                         |                    | 0.207   |
| 60%-69%                        | 12 (4.4%)       | 4 (4.6%)           | 7 (5.0%)                | 1 (2.0%)           |         |
| 70%-89%                        | 195 (70.6%)     | 55 (63.2%)         | 99 (71.2%)              | 41 (82.0%)         |         |
| 90%-99%                        | 69 (25.0%)      | 28 (32.2%)         | 33 (23.7%)              | 8 (16.0%)          |         |
| Residual stenosis              | 10.0 (0.0–29.2) | 5.0 (0.0–20.0)     | 10.0 (0.0–30.0)         | 20.0 (7.0–30.0)    | 0.003   |

Values are presented as percentage or median (interquartile range)
Overall, the periprocedural complication rate was 3.3% (9 cases). The rate for any type of stroke or death was 3.0% (8 cases). Six patients (2.2%) had ischemic strokes, two patients (0.7%) had hemorrhagic strokes, and one (0.3%) had a myocardial infarction (Table 2). Analyzing results according to pretreatment statin dose, patients in the high-dose statin group had two complications, the standard-dose statin group had four complications, and the no-statin group had three complications. This difference was not statistically significant ($p = 0.923$). When analyzed depending on the use of pretreatment statin, no difference in periprocedural complications were found between the groups (Supplementary Table II).

After adjusting for confounders, including hyperlipidemia, residual stenosis and pre-stenting dilatation, statin-pretreatment remained a non-independent factor of periprocedural complications after CAS (Standard-dose statin: odds ratio, 1.003; 95% CI [0.953, 1.055]; High-dose statin: odds ratio, 1.012; 95% CI [0.950, 1.079]) (Table 3). CA trend test also did not demonstrate a trend in the proportion of periprocedural complications across increasing statin equivalent dose ($p = 0.919$).

### Table 2

|                      | Total (N = 276) | No-statin (N = 87) | Standard-dose (N = 139) | High-dose (N = 50) | $p$-value |
|----------------------|----------------|--------------------|-------------------------|--------------------|-----------|
| Pre-stenting dilatation | 266 (96.4%)    | 81 (93.1%)         | 137 (98.6%)             | 48 (96.0%)         | 0.101     |
| Post-stenting dilatation | 106 (38.4%)  | 27 (31.0%)         | 58 (41.7%)              | 21 (42.0%)         | 0.232     |

Values are presented as percentage or median (interquartile range)
### Table 3
Multivariable logistic regression for complications within 30 days of stenting for asymptomatic carotid artery stenosis

|                | Odds Ratio | 95% Confidence Interval | p-value |
|----------------|------------|-------------------------|---------|
| Hyperlipidemia | 0.967      | 0.922–1.013             | 0.163   |
| Residual stenosis | 0.999      | 0.998–1.001             | 0.894   |
| Pre-stenting dilatation | 1.032      | 0.920–1.158             | 0.588   |
| Statin dose     |            |                         |         |
| No statin       | Reference  | Reference               | Reference |
| Standard-dose statin | 1.003      | 0.953–1.055             | 0.895   |
| High-dose statin | 1.012      | 0.950–1.079             | 0.695   |

### Discussion

In our study, CAS 30-day periprocedural complication rate was 3.3% (9 of 276), which is consistent with previous studies in asymptomatic carotid artery stenosis.\(^4\),\(^12\) The overall periprocedural complications were not different between the three groups according to the pretreatment statin dose, and showed no linear trend of association to the statin dose. In addition, when the analysis was conducted comparing use to no-use of statin before CAS, there was no difference in the results.

Statin is considered an option to prevent periprocedural complications. Pretreatment statin use has been shown by previous studies to significantly decrease the frequency of cardiovascular, cerebrovascular, and secondary stroke events after vascular procedures or endarterectomy.\(^9\),\(^16\)–\(^22\) This effect might be due to multiple effects of statin, such as plaque stabilization and reduction of intravascular thrombosis. Preventive effects of statins are supported by findings of statin use being associated with reduced plaque volume and atheroma regression in the carotid circulation,\(^23\) in addition to less embolic debris during CAS.\(^24\) However, all of these studies included both symptomatic and asymptomatic patients.\(^25\) There is no study about the pretreatment statin effects on periprocedural complications of CAS limited to asymptomatic patients. In contrast to studies with symptomatic carotid artery stenosis, our study demonstrated no significant dose-dependent or absolute statin effects in preventing periprocedural complications in asymptomatic patients with carotid artery stenosis. There is a possible explanation for this finding. A previous study suggests that infiltration of the fibrous cap with foam cells, fibrous cap thinning, and plaque rupture are more commonly presented in patients with symptomatic carotid artery stenosis than in asymptomatic patients.\(^26\) Similar to acute coronary syndromes, plaque ruptures are an important pathoetiologial factor of neurological deterioration as a result of carotid artery stenosis. During stent deployment, embolism from the carotid artery plaque is generally responsible for the majority of new ischemic lesions. Based on this study, the multiple pleiotropic effects of statins did not alter the risk of periprocedural complications in asymptomatic patients with carotid artery stenosis.
because the plaques are generally more stable. Nonetheless, caution is advised in the interpretation of our results, which showed that there is no protective effect of statin, limited to the periprocedural period. Statins are known to have protective effects on long-term outcome.\(^{(6, 27)}\)

Here, we found LDL lowering effects of statin. However, statins have multiple pleiotropic effects, such as promoting endothelial function, reducing inflammation, affecting arterial myocyte proliferation, migration and apoptosis, as well as regulating platelet activity, plaque stability, and the coagulation process. Therefore, LDL is not the only concern when contemplating successful risk reduction.\(^{(28, 29)}\) As previous studies suggest, statin treatment should be given in accordance to the global vascular risk factor and not chiefly according to base LDL level\(^{(30, 31)}\). Consistently, our results indicated that LDL levels alone did not correlate with the risk of periprocedural complications.

Our study has several limitations. First, it includes a relatively small sample, and it is a retrospective study. Second, there was a lack of data for pretreatment duration. Thus, it was not possible to evaluate where this parameter was associated with periprocedural complications. Third, we lacked information on the type of stents used. Previous studies have shown a higher risk of periprocedural stroke in patients treated with open-cell stent devices compared to those given closed-cell devices.\(^{(32, 33)}\) Fourth, we cannot be certain that there were no differences in the original plaque morphology or vascular anatomy of the groups considered, which might have differentially influenced the risk of periprocedural complications. Therefore, our results should be verified in randomized trials or prospective trials with larger datasets.

In conclusion, this study shows that statin pretreatment did not have dose-dependent or absolute effects on periprocedural complications risk in patients undergoing CAS for the treatment of asymptomatic carotid artery stenosis.

**Declarations**

**Acknowledgements**

Not Applicable

**Contributions**

S-HJ analyzed and interpreted the data and wrote the manuscript. H-MK, D-HK, H-JP, S-IS, H-C analyzed and interpreted the data, and revised the manuscript. J-HH designed and conceptualized the study, interpreted the data, and revised the manuscript.

**Ethics approval and consent to participate**

The protocol for data collection was approved by the Institutional Review Board (IRB) of Keimyung University Dongsan Hospital (IRB number 2017-05-042). Our study was implemented in accordance with the ethical standards of the 1964 Declaration of Helsinki and its lateral amendments. The need for
written informed consent was waived because of the retrospective nature of this study. IRB of Keimyung University Dongsan Hospital (IRB number 2017-05-042) waived the need for informed consent.

**Consent for publication**

Not Applicable

**Competing interests**

The authors declare that they have no competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not for profit sectors.

**Availability of data and material**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

1. Young KC, Jain A, Jain M, Replogle RE, Benesch CG, Jahromi BS. Evidence-based treatment of carotid artery stenosis. Neurosurg Focus. 2011;30(6):E2.
2. White H, Boden-Albala B, Wang C, Elkind MS, Rundek T, Wright CB, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation. 2005;111(10):1327-31.
3. Lichtman JH, Jones MR, Leifheit EC, Sheffet AJ, Howard G, Lal BK, et al. Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014. JAMA. 2017;318(11):1035-46.
4. Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, et al. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. N Engl J Med. 2016;374(11):1011-20.
5. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor's Choice - Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(1):3-81.
6. Verzini F, De Rango P, Parlini G, Giordano G, Caso V, Cieri E, et al. Effects of statins on early and late results of carotid stenting. J Vasc Surg. 2011;53(1):71-9; discussion 9.
7. Reiff T, Amiri H, Rohde S, Hacke W, Ringleb PA. Statins reduce peri-procedural complications in carotid stenting. Eur J Vasc Endovasc Surg. 2014;48(6):626-32.
8. Groschel K, Ernemann U, Schulz JB, Nagele T, Terborg C, Kastrup A. Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death. Radiology. 2006;240(1):145-51.

9. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke. 2005;36(10):2072-6.

10. Hong JH, Sohn SI, Kwak J, Yoo J, Chang HW, Kwon OK, et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke. 2017;48(7):1890-4.

11. North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke. 1991;22(6):711-20.

12. Brott TG, Hobson RW, 2nd, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11-23.

13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.

14. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvasatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-7.

15. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke. 2011;42(8):e464-540.

16. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105(6):691-6.

17. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110(6):674-8.

18. McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, Jain S, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg. 2005;42(5):829-36; discussion 36-7.

19. Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39(12):3297-302.

20. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-63.
21. Antoniou GA, Hajibandeh S, Hajibandeh S, Vallabhaneni SR, Brennan JA, Torella F. Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. J Vasc Surg. 2015;61(2):519-32 e1.

22. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980-9.

23. Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF, Jr. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson. 2011;13:37.

24. Tadros RO, Vouyouka AG, Chung C, Malik RK, Krishnan P, Ellozy SH, et al. The effect of statin use on embolic potential during carotid angioplasty and stenting. Ann Vasc Surg. 2013;27(1):96-103.

25. Texakalidis P, Giannopoulos S, Jonnalagadda AK, Chitale RV, Jabbour P, Armstrong EJ, et al. Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. J Endovasc Ther. 2018;25(5):624-31.

26. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg. 1996;23(5):755-65; discussion 65-6.

27. Hussain MA, Saposnik G, Raju S, Salata K, Mamdani M, Tu JV, et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc. 2018;7(16):e009745.

28. Perler BA. Should statins be given routinely before carotid endarterectomy? Perspect Vasc Surg Endovasc Ther. 2007;19(3):240-5.

29. de Lorenzo F, Feher M, Martin J, Collot-Teixeira S, Dotsenko O, McGregor JL. Statin therapy-evidence beyond lipid lowering contributing to plaque stability. Curr Med Chem. 2006;13(28):3385-93.

30. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.

31. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative G. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-67.

32. Doig D, Turner EL, Dobson J, Featherstone RL, Lo RT, Gaines PA, et al. Predictors of Stroke, Myocardial Infarction or Death within 30 Days of Carotid Artery Stenting: Results from the International Carotid Stenting Study. Eur J Vasc Endovasc Surg. 2016;51(3):327-34.

33. Jansen O, Fiehler J, Hartmann M, Bruckmann H. Protection or nonprotection in carotid stent angioplasty: the influence of interventional techniques on outcome data from the SPACE Trial. Stroke. 2009;40(3):841-6.